CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth

SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in proven, science-backed natural ingredients and products, today announced that it has modified its existing outstanding notes to include a conversion feature pursuant to which the outstanding balance of the notes may be converted into common shares of the Company at a fixed conversion price of $0.06 per share. "We are pleased with the successful completion of a comprehensive debt restructuring, marking a significant milestone in the Company's strategic plan to enhance financial flexibility and accelerate long-term growth," said Joseph Dowling, CEO of CV Sciences.